Asthma Trial, Recruiting (NCT06196034)

Asthma Trial, Recruiting NCT06196034 Sponsor: Chinese University of Hong Kong Condition: Asthma

Printed from Voxsanity (voxsanity.com.au) — NCT06196034 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Asthma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have a confirmed diagnosis of asthma, meaning they have a consistent history of the condition and past test results showing that their airways vary in how open or blocked they are, confirmed by breathing tests when their asthma is stable.
People who are able to read and sign a consent form agreeing to take part in the study.
People without an asthma diagnosis may also be eligible to join as a control (comparison) participant.

Who may not be able to join:

People who are currently experiencing an asthma flare-up (worsening of symptoms). However, the trial site may allow someone to join 6 weeks after they have recovered from a flare-up (confirm with trial site).
People who have, or have had, certain other lung or airway conditions — such as bronchiectasis, lung damage from tuberculosis, tuberculosis affecting the airways, or lung cancer — where a doctor judges this to be relevant.
People who are currently diagnosed with pneumonia or acute bronchitis (a short-term infection causing airway inflammation).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David SC Hui, Chinese University of Hong Kong

Phone: 35053133

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06196034

Sponsor: Chinese University of Hong Kong

Phase: Not Applicable

Status: Recruiting

Condition: Asthma

Trial contact: 35053133

More information: https://clinicaltrials.gov/study/NCT06196034

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have a confirmed diagnosis of asthma, meaning they have a consistent history of the condition and past test results showing that their airways vary in how open or blocked they are, confirmed by breathing tests when their asthma is stable.
People who are able to read and sign a consent form agreeing to take part in the study.
People without an asthma diagnosis may also be eligible to join as a control (comparison) participant.

Who may not be able to join:

People who are currently experiencing an asthma flare-up (worsening of symptoms). However, the trial site may allow someone to join 6 weeks after they have recovered from a flare-up (confirm with trial site).
People who have, or have had, certain other lung or airway conditions — such as bronchiectasis, lung damage from tuberculosis, tuberculosis affecting the airways, or lung cancer — where a doctor judges this to be relevant.
People who are currently diagnosed with pneumonia or acute bronchitis (a short-term infection causing airway inflammation).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Chinese University of Hong Kong

Registry

ClinicalTrials.gov

Start date

1 March 2024

Est. completion

4 January 2028

Where this trial is recruiting

Hong Kong

Primary endpoints

association between genetic polymorphisms and various severities of asthma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov